New research suggests certain diabetes medications may also lower the risk of obesity-related cancers.
These medications, known as GLP-1, include popular brands like Wegovy and Ozempic. They help control blood sugar levels and reduce appetite.
A recent study analyzed data from over 170,000 patients across 43 US healthcare systems. It compared those taking GLP-1 medications to those taking traditional diabetes medications like sitagliptin.
The results show that GLP-1 users had a 7% lower risk of obesity-related cancers and an 8% lower overall death rate over a four-year period.
While the study doesn’t prove GLP-1 directly reduces cancer risk, it’s an interesting starting point for further research – especially in women, who showed more significant results than men.
GLP-1 medications are currently approved for treating both diabetes and obesity in several countries, including the US.
The findings were presented at the American Society of Clinical Oncology meeting in Chicago and are gaining attention worldwide.
Source: AP
